Becton, Dickinson and Company (BDX) To Go Ex-Dividend on June 10th

Becton, Dickinson and Company (NYSE:BDX) announced a quarterly dividend on Tuesday, April 30th, RTT News reports. Investors of record on Monday, June 10th will be paid a dividend of 0.95 per share by the medical instruments supplier on Friday, June 28th. This represents a $3.80 annualized dividend and a yield of 1.63%. The ex-dividend date is Monday, June 10th.

Becton, Dickinson and Company has increased its dividend by an average of 4.8% per year over the last three years and has increased its dividend annually for the last 52 consecutive years. Becton, Dickinson and Company has a dividend payout ratio of 26.5% meaning its dividend is sufficiently covered by earnings. Research analysts expect Becton, Dickinson and Company to earn $14.32 per share next year, which means the company should continue to be able to cover its $3.80 annual dividend with an expected future payout ratio of 26.5%.

Becton, Dickinson and Company Trading Down 0.3 %

Shares of NYSE BDX opened at $233.81 on Thursday. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of 0.56. The stock’s 50 day simple moving average is $238.75 and its 200 day simple moving average is $240.71. The company has a market cap of $67.55 billion, a price-to-earnings ratio of 55.41, a price-to-earnings-growth ratio of 1.93 and a beta of 0.43. Becton, Dickinson and Company has a 12-month low of $229.40 and a 12-month high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share for the quarter, topping analysts’ consensus estimates of $2.39 by $0.29. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The company had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.73 billion. During the same period in the prior year, the business posted $2.98 EPS. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. Equities research analysts expect that Becton, Dickinson and Company will post 12.94 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on BDX. Barclays boosted their target price on Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a research note on Monday, February 5th. Raymond James increased their target price on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $280.00.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares in the company, valued at approximately $542,348.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the transaction, the executive vice president now owns 5,381 shares in the company, valued at $1,252,750.61. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the sale, the senior vice president now directly owns 2,276 shares in the company, valued at $542,348.04. The disclosure for this sale can be found here. Insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.